<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9"><gtr:id>31AF7C42-D7C4-47FF-A5D8-19AADBAD30A9</gtr:id><gtr:name>MRC Human Immunology Unit</gtr:name><gtr:address><gtr:line1>Weatherall Inst of Molecular Medicine</gtr:line1><gtr:line2>John Radcliffe Hospital</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 9DS</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/65AF1713-F5D3-41D8-A71A-DA5E41A4F797"><gtr:id>65AF1713-F5D3-41D8-A71A-DA5E41A4F797</gtr:id><gtr:firstName>Vincenzo</gtr:firstName><gtr:surname>Cerundolo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137884181"><gtr:id>E5502093-9F0A-47DB-A18D-0D00420AD7F1</gtr:id><gtr:title>Analysis of the cellular mechanisms involved in the generation of melanoma specific cytotoxic T lymphocyte epitopes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137884181</gtr:grantReference><gtr:abstractText>a) nature of research - Patients with cancers such as melanoma can make an immune response to the tumour and the immune cells can destroy the cancer. Although this has been demonstrated in the test tube it does not appear to work will in the body. This work identifies this immune response in patients and is beginning to work out why the immune attack is not as strong as it should be. This could lead to treatments aimed at strengthening the immune response.||b) prospective outcomes - Regression of melanomas||c) health benefits - Potential treatment of melanomas and possible application of any therapies to other tumours</gtr:abstractText><gtr:technicalSummary>Research in my laboratory is focused on the understanding of the mechanisms which control the cell-cell interplay required for optimal expansion and activation of tumour-specific T cell populations. Our previous studies have established that in a significant proportion of A2 positive melanoma patients, CTL specific for the Melan-A epitope 26-35 can be detected ex vivo by tetramer staining. Our results indicate that in vivo priming of melan-A-specific CTL is a late phenomenon, since only stage III or stage IV patients have an active immune response, while stage I/II patients and healthy volunteers have melan-A26/7-35-specific CTL with functional and phenotypic markers of naive population.||The main challenge for tumour immunotherapy is probably to jumpstart the CTL response at a far earlier stage of disease, to maximize the possibility for clinical impact. Powerful polyvalent immunogens capable of reliably priming tumour-specific CD8+ T lymphocytes are needed, and developing agents that are also simple to store and administer will greatly assist their wider use in early disease. Advances in molecular technology have permitted the design of synthetic protein vaccines, providing immunotherapy with a degree of specificity that has not been possible using traditional vaccines based on live attenuated pathogens or whole inactivated organisms. Such specificity is providing a platform for the design of T cell therapy for infectious diseases and cancer. It is therefore important to optimise vaccination strategies, using protocols capable of jump starting immune responses specific to recombinant protein antigens. The combined use of subunit vaccines with compounds that activate innate responses should be exploited in future vaccination strategies, in an effort to overcome the limitation of immunodominant viral-specific CTL responses.||Over the last three years we have characterised a novel vaccination strategy based on the activation of invariant NKT cells (iNKT cells), which results in the rapid maturation of DC and expansion of antigen specific T and B lymphocytes. The results of structural, kinetic and functional studies have facilitated the process of rational optimisation of iNKT agonists and have led to the identification of compounds capable of binding to CD1d molecules and activating human and mouse iNKT cells, resulting in rapid DC maturation and T cell priming. ||Experimental design||a) tissues, cells, animals used - mouse models, patient studies||b) techniques/approaches - Molecular and cellular immunology||c) measurements/outcomes - Understanding of human immune responses to skin cancer</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1172288</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Institute for Cancer Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with LICR</gtr:description><gtr:id>0A09E20F-E9CA-4696-9407-AA78DF7F1BD7</gtr:id><gtr:impact>15386406 16339586</gtr:impact><gtr:outcomeId>8D50845B792-1</gtr:outcomeId><gtr:partnerContribution>Supply of reagents and clinical trial support and infrastructure</gtr:partnerContribution><gtr:piContribution>Analysis of tumour specific T cell responses in melanoma patients participating to LICR sponsored trials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>A level student visits 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5CD1456D-29B6-4BF9-83A2-05031BF76080</gtr:id><gtr:impact>2 students were hosted by members of my group for a &amp;quot;work experience week'

school would like to repeat the program in 2013</gtr:impact><gtr:outcomeId>KJWK3GV3oJx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Annual Review 2008-09</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10033B92-75C5-494A-BBE4-0FB724BB625D</gtr:id><gtr:impact>General description of the my research programme to a general audience

general interests towards the research programmes that we are developing in my laboratory and within the MRC Human Immunology Unit.</gtr:impact><gtr:outcomeId>43B1EC5B80D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Alumni</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>51C3A144-9EF5-449E-8C4A-160A3C9BEFFF</gtr:id><gtr:impact>Prof. Cerundolo gave a lecture on tumour immunology and cancer vaccines to a group of 130 Oxford Alumni (average age 60 years)

Talk was well received</gtr:impact><gtr:outcomeId>oAzHzYGfm4T</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford University Department for Continuing Education Human and Veterinary Vaccinology Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6B7DACD5-62F6-4871-9EDC-F0DA1EC614D2</gtr:id><gtr:impact>During the last 2 years, the Oxford University Department for Continuing Education http://www.conted.ox.ac.uk/courses/C900-1 
has launched a leading educational programme in Vaccinology, tailored to the needs of industry in the UK and beyond, by sharing the expertise of several investigators, both at the Institute for Animal Health and across the University of Oxford, complemented by the views and experience of distinguished outside speakers. The courses run in 2010 were fully subscribed and received very good feedback from the participants. The satisfaction scores were very high: 88% for the Human and Veterinary Vaccinology; 77% for the Clinical Vaccine Development course; and 81% for the Vaccine Biomanufacturing course.
In November 2011 Prof. Cerundolo gave a talk entitled 'An Introduction to Tumour Immunology'

Course was well attended</gtr:impact><gtr:outcomeId>AdujC2g5L82</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research Institute USA (A phase I study of NY-ESO-1 ISCOM followed by recombinant fowlpox NY-ESO1 (rF-NY-ESO) in patients with NY-ESO-1 positive tumours)</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Cancer Research Institute (CRI)</gtr:fundingOrg><gtr:id>2F101B5B-34CC-4D46-B267-51C090499688</gtr:id><gtr:outcomeId>0B40BFAD0EB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Oxford Cancer Imaging Centre</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>48C8B951-5EAA-4024-BB14-9D150F039F54</gtr:id><gtr:outcomeId>0E7F04A081F0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>857627</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (Novel invariant NKT cell agonists as adjuvants for antigen specific T and B cell responses)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1F8C1F47-94E8-4FA6-BCE0-D6E4BCC86AC4</gtr:id><gtr:outcomeId>89BBC83A4200</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>134000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Immunotherapy</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>1FD926CE-FA1F-4999-815E-652FCC07FDAC</gtr:id><gtr:outcomeId>43D705954950</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (Analysis of tumour-specific responses in cancer patients)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>B9A94BA0-19DC-4386-ADAE-7DAC79ABD38B</gtr:id><gtr:outcomeId>EA2F7763C5F0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>112000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DC-THERA Network of Excellence (7.6m euros across 32 participants)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D53065E5-3B8D-4EC8-9D79-402FB2C2BB05</gtr:id><gtr:outcomeId>3583F19D82A0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2005-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>190000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Immunonanomap</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>7CDD1F0B-2E7D-4370-A6D2-CBF926F708C8</gtr:id><gtr:outcomeId>B3A08725DAA0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research Institute USA (Affinity maturated NY-ESO-1 157-165/HLA-A2 specific antibodies for targeting and detection of NY-ESO-1 expressing tumours)</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Cancer Research Institute (CRI)</gtr:fundingOrg><gtr:id>DD0A0A41-115C-4B04-9BA8-48379111F1DB</gtr:id><gtr:outcomeId>812B8E5FFBF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to materials and methods for improved vaccination strategies and in particular to the use of lentivirus comprising nucleic acid encoding and antigen, or antigen presenting cells transduced with such lentivirus, to stimulate immune responses against the encoded antigen, in heterologous prime-boost vaccination regimes.</gtr:description><gtr:grantRef>MC_U137884181</gtr:grantRef><gtr:id>283C8FB7-4AA6-4998-B8D0-CF94A8568A3B</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>22C1C6BF8E5</gtr:outcomeId><gtr:patentId>US2006257416</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Materials and methods for improved vaccination</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention provides novel vaccination strategies based on a prime-boost vaccination regimen. The inventors have determined improved ways of boosting an immune response in a patient previously primed or exposed to a plurality of epitopes. The improved method requires the epitopes in the boosting phase to be administered individually, i.e. held on separate peptide constructs.</gtr:description><gtr:grantRef>MC_U137884181</gtr:grantRef><gtr:id>546842E5-C76E-42B3-BAAE-057501D74A9B</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>040423C2FC6</gtr:outcomeId><gtr:patentId>US2008260780</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Materials and methods relating to improved vaccination strategies</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Strategic Review of Human Immunology in the UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57C3FB8E-68ED-42CB-AAE8-C7625839B48A</gtr:id><gtr:outcomeId>9BE1DE406C1</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Strategic impact of human immunology research in the UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2C7D5AA1-61A0-4FBB-BE6C-9CDCFA5D057E</gtr:id><gtr:outcomeId>bG8Kiwg8oub</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E9A81B42-FBEC-4959-8603-7E814B47791A</gtr:id><gtr:title>Structures of an MHC class I molecule from B21 chickens illustrate promiscuous peptide binding.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68719213bb1c312f00046e91edb42c17"><gtr:id>68719213bb1c312f00046e91edb42c17</gtr:id><gtr:otherNames>Koch M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>V75ic8V5TyS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E70FD28-B750-43ED-AA0E-ADD3A49ADC0C</gtr:id><gtr:title>Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54116faae123c2097a55cead7889d479"><gtr:id>54116faae123c2097a55cead7889d479</gtr:id><gtr:otherNames>Chen JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>106D73B1F03</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5F7F697-F188-463C-99A8-DD4A12A7E203</gtr:id><gtr:title>Rational design of indoleamine 2,3-dioxygenase inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95ce98b02cc8679412097a2e6769a9af"><gtr:id>95ce98b02cc8679412097a2e6769a9af</gtr:id><gtr:otherNames>R?hrig UF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>qabkk4kZEyC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1EF697E-94FF-45AB-AC27-769FAED98020</gtr:id><gtr:title>Rational development of high-affinity T-cell receptor-like antibodies.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bd7185a0698864c4440b2dbd1fed93"><gtr:id>a3bd7185a0698864c4440b2dbd1fed93</gtr:id><gtr:otherNames>Stewart-Jones G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58aabcbe089025.54684937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68696F80-6841-4381-B7E3-84D4CCD7D5D2</gtr:id><gtr:title>T cell receptors get back to basics.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5e3a7dc78f1cd307cc16ee3d61ffa18"><gtr:id>d5e3a7dc78f1cd307cc16ee3d61ffa18</gtr:id><gtr:otherNames>Jones EY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>672CB9947FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E67EA0B-08B9-419A-82B7-F0E11FA0B508</gtr:id><gtr:title>Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.</gtr:title><gtr:parentPublicationTitle>Cancer immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94c5d51a9966d1e0656be121d111f73d"><gtr:id>94c5d51a9966d1e0656be121d111f73d</gtr:id><gtr:otherNames>Ling KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1424-9634</gtr:issn><gtr:outcomeId>WSzNd57BSqh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5681E27-83AF-4B48-B8AB-DD18AE5169C1</gtr:id><gtr:title>Modulation of CD103 expression on human colon carcinoma-specific CTL.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94c5d51a9966d1e0656be121d111f73d"><gtr:id>94c5d51a9966d1e0656be121d111f73d</gtr:id><gtr:otherNames>Ling KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>05318D54D84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32179285-4E49-48F5-BFE3-AA0DE3E91180</gtr:id><gtr:title>Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>q917Jb6fe3V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91272F42-1833-4FEA-B3D4-CF07F1DC767C</gtr:id><gtr:title>Constitutively active Lck kinase in T cells drives antigen receptor signal transduction.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1acd48b435d6ed60d479e0726c769f"><gtr:id>ff1acd48b435d6ed60d479e0726c769f</gtr:id><gtr:otherNames>Nika K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>XnxtGzWCpKg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18EE9D02-80FB-4199-84F9-34ABED7E7FB9</gtr:id><gtr:title>Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a45bc2b3cb7e3f4064a9dce2caec9a"><gtr:id>49a45bc2b3cb7e3f4064a9dce2caec9a</gtr:id><gtr:otherNames>Silk JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58aabcbf34bf14.22982925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEA16E76-7F65-4FEB-94C5-0BADEB3CF28D</gtr:id><gtr:title>[Glycosphingolipids Gb3 and iGb3. In vivo roles in hemolytic-uremic syndrome and iNKT cell function].</gtr:title><gtr:parentPublicationTitle>Der Pathologe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71c646940318407a3861110bf2de944"><gtr:id>f71c646940318407a3861110bf2de944</gtr:id><gtr:otherNames>Porubsky S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0172-8113</gtr:issn><gtr:outcomeId>g1Xgc7LfsxH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D81477DC-55BD-4BDE-A7A6-5F4BF6253FA3</gtr:id><gtr:title>Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76fc7c73e061efd4937e7e37e9d338ce"><gtr:id>76fc7c73e061efd4937e7e37e9d338ce</gtr:id><gtr:otherNames>Zeissig S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>c1RpuiLnka5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE756346-274D-47D6-B146-B3C5FDCE676D</gtr:id><gtr:title>Aberrant selection and function of invariant NKT cells in the absence of AP-1 transcription factor Fra-2.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b939393c193eac4c9980ecb32b4d1da2"><gtr:id>b939393c193eac4c9980ecb32b4d1da2</gtr:id><gtr:otherNames>Lawson VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>ShC3XBbqxLF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>235CA025-7174-4928-A3B0-7D812B875489</gtr:id><gtr:title>Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/817d3278c27c6117071a3801798f218b"><gtr:id>817d3278c27c6117071a3801798f218b</gtr:id><gtr:otherNames>Matthews KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>57F37AB2C57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CFD5ADB-AAB8-401E-B2DB-48B4046CB18E</gtr:id><gtr:title>T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df7a26418741d87b24266d14011dc7f5"><gtr:id>df7a26418741d87b24266d14011dc7f5</gtr:id><gtr:otherNames>Mallevaey T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>LgYxz6vAHCz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>473D4567-5FED-4D97-85CD-1F4DD54640FE</gtr:id><gtr:title>MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc6513a22150450d62eea3bbff9d2e80"><gtr:id>bc6513a22150450d62eea3bbff9d2e80</gtr:id><gtr:otherNames>Held G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>tRdADA8q1ko</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A8F2488-F0AB-4419-BBC9-C710236F52B2</gtr:id><gtr:title>Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71c646940318407a3861110bf2de944"><gtr:id>f71c646940318407a3861110bf2de944</gtr:id><gtr:otherNames>Porubsky S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>HQ1Jy43UedR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BA44DF9-D40B-48E3-A4BC-89A92C4D295E</gtr:id><gtr:title>Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/588d0371c18b2c4cc6b6fdbc1bdd395f"><gtr:id>588d0371c18b2c4cc6b6fdbc1bdd395f</gtr:id><gtr:otherNames>Aleksic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>n9vdG8ikuiz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3F183B6-BBF8-4309-BBFD-BFD82EE1F150</gtr:id><gtr:title>Early acquisition of cytolytic function and transcriptional changes in a primary CD8+ T-cell response in vivo.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0ab83ce5a962ead03102dd5b014052"><gtr:id>5b0ab83ce5a962ead03102dd5b014052</gtr:id><gtr:otherNames>Chiu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>Lna4bGrnkiN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A936D778-D359-4D48-9259-9A05E1047C00</gtr:id><gtr:title>Analysis of frequency and phenotype of antigen-specific T cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac7e26fc7687dfd51f87121e4632ed91"><gtr:id>ac7e26fc7687dfd51f87121e4632ed91</gtr:id><gtr:otherNames>Stock A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>SKUDxr7K6Up</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>122158E2-4DF9-495C-99BD-08BE491D1D8E</gtr:id><gtr:title>A single-chain H-2Db molecule presenting an influenza virus nucleoprotein epitope shows enhanced ability at stimulating CD8+ T cell responses in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2364e09ae5aa8bf7204f7ba871a2610a"><gtr:id>2364e09ae5aa8bf7204f7ba871a2610a</gtr:id><gtr:otherNames>Palmowski MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>sd1aDDjPkee</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1ECC197-5D67-4DC1-A1C3-46E571DA376D</gtr:id><gtr:title>Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20d02bc2c32cfe6f4c97355b57afcfe4"><gtr:id>20d02bc2c32cfe6f4c97355b57afcfe4</gtr:id><gtr:otherNames>Thomas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>fimkmji8BUb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23D49070-7396-49B6-8288-CED47712F9AD</gtr:id><gtr:title>B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed032268c749fe13105b28653a67c1d5"><gtr:id>ed032268c749fe13105b28653a67c1d5</gtr:id><gtr:otherNames>Barral P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58aabcbf0e2a59.57964934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2F35C61-2B3F-4B3E-8D98-A68716E4A278</gtr:id><gtr:title>Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d547e90cc384e09a297316e7446f9b8"><gtr:id>6d547e90cc384e09a297316e7446f9b8</gtr:id><gtr:otherNames>Wooldridge L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>oYmo5FuVdCX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C59061A6-9EDD-42A6-A733-CDE252CB351D</gtr:id><gtr:title>Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d09a00d7c724d63247a15b7e5419d9c5"><gtr:id>d09a00d7c724d63247a15b7e5419d9c5</gtr:id><gtr:otherNames>De Santo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>BED37F68F91</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F2BF411-1B1C-48AB-BF0B-3495C99ADEEB</gtr:id><gtr:title>Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83d972dc5c6a23943bff292af7c649d9"><gtr:id>83d972dc5c6a23943bff292af7c649d9</gtr:id><gtr:otherNames>Denkberg G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58aabcbfadfdf1.12900750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB7F9644-45AB-4E9F-B450-5A3A3860ED7F</gtr:id><gtr:title>Quantitating T cell cross-reactivity for unrelated peptide antigens.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cd735d2c7ec2a06f5c43d6198a3ebae"><gtr:id>7cd735d2c7ec2a06f5c43d6198a3ebae</gtr:id><gtr:otherNames>Ishizuka J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>a8ciVEHJUbe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F05532FA-CAB9-48C2-BE94-5199919773F4</gtr:id><gtr:title>Structural and functional aspects of lipid binding by CD1 molecules.</gtr:title><gtr:parentPublicationTitle>Annual review of cell and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a45bc2b3cb7e3f4064a9dce2caec9a"><gtr:id>49a45bc2b3cb7e3f4064a9dce2caec9a</gtr:id><gtr:otherNames>Silk JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1081-0706</gtr:issn><gtr:outcomeId>58aabcbfd1ce89.40305020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BC8A3AC-104A-4A4A-8A11-2AA0F66CE8CF</gtr:id><gtr:title>CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed032268c749fe13105b28653a67c1d5"><gtr:id>ed032268c749fe13105b28653a67c1d5</gtr:id><gtr:otherNames>Barral P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>DEKZ1rDcu2r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BE5F715-EF26-4C46-95E6-73E7E7012D01</gtr:id><gtr:title>Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7ce540024a50b8bd8ff7d2427850e4"><gtr:id>6d7ce540024a50b8bd8ff7d2427850e4</gtr:id><gtr:otherNames>Lopes L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>10CE2B8D7A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAA7FF69-8CCA-4DE6-B871-5234C142987C</gtr:id><gtr:title>Improved localization of cellular membrane receptors using combined fluorescence microscopy and simultaneous topography and recognition imaging.</gtr:title><gtr:parentPublicationTitle>Nanotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b2aa54635d1b2061138033a1398eb2"><gtr:id>47b2aa54635d1b2061138033a1398eb2</gtr:id><gtr:otherNames>Duman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0957-4484</gtr:issn><gtr:outcomeId>LSTP5i6GHAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B403063-6B86-42DE-8974-E430090E19C9</gtr:id><gtr:title>NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc289e914289c5f88746ad9fbb52e789"><gtr:id>fc289e914289c5f88746ad9fbb52e789</gtr:id><gtr:otherNames>Gnjatic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>T4BbWfDEugE</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137884181</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>